Biotech Startups

EpiBone engineers bone tissue from stem cells for regenerative medicine and clinical reconstruction, serving patients requiring bone grafts or craniofacial repair. The company translates tissue engineering research into therapeutic products for orthopedic and surgical applications.

7 investors

Epsilogen develops antibody therapeutics based on the IgE, IgA, and IgG immunoglobulin isotypes for the treatment of cancer, matching each isotype to specific tumor types and combining isotypes into single antibody molecules. Its lead candidate, MOv18 IgE, targets folate receptor alpha and is in clinical development for ovarian cancer.

7 investors

F2G is a biotechnology company developing novel antifungal therapies to treat rare, life-threatening fungal infections in defined patient populations. Its work centers on new drug science aimed at expanding treatment options against fungal pathogens.

7 investors

Formation Bio develops drugs through partnerships with health systems, academic medical centers, and research sites, focusing on clinical trials in dermatology, rheumatology, and cardiometabolic diseases. The company provides trial management infrastructure, monitoring, technology, and enrollment support to accelerate drug development.

7 investors

Formo uses precision fermentation to produce bio-identical milk proteins, such as its Formo Casein, that replicate the functionality, texture, and taste of dairy without animals. The company applies this technology to create animal-free dairy products like cheese.

7 investors

Gallant develops regenerative medicine therapies for veterinary care, bringing treatments from laboratory research into clinical practice for pets.

7 investors

Genecis commercializes the production of polyhydroxyalkanoate (PHA), a biodegradable polymer made from bacteria that consume organic waste, offering a sustainable alternative to petroleum-based plastics for packaging, textiles, medical devices, and other applications. The company applies circular economy principles to create high-quality, eco-friendly products that break down naturally without microplastic pollution.

7 investors

Genesis develops GEMS, an AI platform for drug discovery that identifies and optimizes drug candidates. The company partners with pharmaceutical firms like Incyte and Gilead to accelerate the identification and optimization of new drugs.

7 investors

Genomenon uses AI to read biomedical literature and expert scientists to curate variant- and patient-level genomic evidence, delivering regulatory-grade real-world evidence. Its products, including Mastermind and CKB, serve drug development teams and clinical genetic testing labs for variant interpretation and drug program decisions.

7 investors

Gesynta Pharma develops pharmaceutical treatments for inflammation and pain by selectively inhibiting the enzyme mPGES-1. Its lead candidate vipoglanstat is in phase 2 clinical trials as a non-hormonal, non-opioid treatment for endometriosis, alongside a second candidate GS-073 for chronic inflammatory pain.

7 investors

Glycomine develops therapeutics for rare diseases, many of which currently lack disease-modifying treatment options. The company focuses on addressing unmet medical needs in the rare disease space.

7 investors

7 investors

Heartseed develops cardiac regenerative medicine, creating heart muscle cells from iPS cells for transplantation to treat heart failure, with its lead pipeline HS-001 nearing clinical trials. The company targets patients with heart failure caused by conditions such as myocardial infarction, with reference markets in Japan and the US.

7 investors

HotSpot Therapeutics is a drug discovery company developing small-molecule allosteric medicines by targeting "natural hotspots" — regulatory on/off switches on proteins. Its Smart Allostery platform combines structure-function analysis, pharmacology, chemistry, and AI to discover treatments for autoimmune diseases.

7 investors

Humane Genomics develops oncolytic viral therapies designed to selectively target and kill cancer cells using engineered RNA viruses, particularly Vesicular Stomatitis Virus. The company leverages a computational platform for viral genome design and engineering to create cancer treatments with improved safety, efficacy, and manufacturing efficiency.

7 investors

Iambic develops AI technologies for drug discovery, using a high-throughput experimental platform to design small-molecule medicines and advance a pipeline of clinical candidates for cancers such as HER2-driven, breast, and ovarian tumors. It serves the pharmaceutical industry through both its own drug pipeline and partnerships.

7 investors

Immunai develops AMICA, a data platform for decoding the immune system to accelerate drug discovery and development. The company serves pharmaceutical and biotech researchers working on inflammatory and oncological therapies.

7 investors

Immusoft develops a cell therapy platform called Immune System Programming (ISP) that engineers a patient's B cells into plasma cells that produce therapeutic proteins after being infused back into the patient. The company focuses on personalized protein therapeutics for patients.

7 investors

Invitae provides genetic testing services to patients and clinicians across the United States, offering broad test offerings and genetic counseling to inform health decisions at every stage of life. Now part of Labcorp, the company leverages a nationwide network of patient service centers and coverage by most health plans to make genetic testing more accessible.

7 investors

The page presents a biography of Dr. Dhingra, a medical oncologist and physician-scientist with experience in oncology drug development. It provides no clear description of the company's own products or services.

7 investors

Johnson & Johnson develops prescription medicines and medical technology across areas including oncology, immunology, neuroscience, cardiopulmonary, cardiovascular, orthopaedics, surgery, and vision. Its two main businesses, Innovative Medicine and MedTech, focus on treating complex diseases through science-based drugs and less invasive, personalized medical devices.

7 investors

Kernal Bio is a synthetic biology company developing selective mRNA drugs to treat serious illnesses, with a focus on cancer therapeutics and improving patient outcomes.

7 investors

Kriya Therapeutics is a biopharmaceutical company that develops and manufactures one-time gene therapies aimed at treating prevalent chronic diseases. It uses AAV-mediated gene therapy approaches across metabolic, neurodegenerative, and other disease areas.

7 investors

Kula Bio develops bacterial propagation and feeding systems that enhance the nitrogen-fixing capabilities of naturally occurring microbes for agricultural applications. The company applies microbial technology originally derived from bionic leaf research to improve crop and turf production.

7 investors